These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21822131)

  • 1. Ocular surface damage by ophthalmic compounds.
    Mantelli F; Tranchina L; Lambiase A; Bonini S
    Curr Opin Allergy Clin Immunol; 2011 Oct; 11(5):464-70. PubMed ID: 21822131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preservatives in eyedrops: the good, the bad and the ugly.
    Baudouin C; Labbé A; Liang H; Pauly A; Brignole-Baudouin F
    Prog Retin Eye Res; 2010 Jul; 29(4):312-34. PubMed ID: 20302969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glaucoma and ocular surface].
    Stefan C; Cojocaru I; Pop A
    Oftalmologia; 2011; 55(1):30-3. PubMed ID: 21774383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergy to ophthalmic preservatives.
    Hong J; Bielory L
    Curr Opin Allergy Clin Immunol; 2009 Oct; 9(5):447-53. PubMed ID: 19697451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of glaucoma in patients with dry eye syndrome].
    Labbé A; Baudouin C
    J Fr Ophtalmol; 2010 Apr; 33(4):285-90. PubMed ID: 20304521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular surface problems following topical medication.
    Bernauer W
    Klin Monbl Augenheilkd; 2002 Apr; 219(4):240-2. PubMed ID: 12022009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
    Baudouin C
    Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
    Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME
    Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ocular toxicity of benzalkonium].
    Chibret H
    Ann Pharm Fr; 2011 Mar; 69(2):108-15. PubMed ID: 21440103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical ophthalmic cyclosporine: pharmacology and clinical uses.
    Donnenfeld E; Pflugfelder SC
    Surv Ophthalmol; 2009; 54(3):321-38. PubMed ID: 19422961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Managing treatment side effects: the respective roles of the active ingredient and the preservative].
    Aptel F; Denis P; Baudouin C
    J Fr Ophtalmol; 2011 Jun; 34(6):409-12. PubMed ID: 21511364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allergic ocular diseases; from mechanisms through treatments].
    Fukagawa K
    Arerugi; 2004 Jan; 53(1):8-13. PubMed ID: 14762325
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM; McDonald MB; Smolek M
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The unwanted ocular effects from topical ophthalmic drugs. Their occurrence, avoidance and reversal.
    Lyle WM; Hopkins GA
    J Am Optom Assoc; 1977 Dec; 48(12):1519-23. PubMed ID: 599247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiglaucoma drops--with or without preservatives].
    Zemba M
    Oftalmologia; 2009; 53(2):26-30. PubMed ID: 19697836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for ocular allergy.
    Leonardi A
    Expert Opin Emerg Drugs; 2005 Aug; 10(3):505-20. PubMed ID: 16083326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targets in dry eye syndrome.
    Peral A; Domínguez-Godínez CO; Carracedo G; Pintor J
    Drug News Perspect; 2008 Apr; 21(3):166-76. PubMed ID: 18560615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term comparative study of the effects of preserved and unpreserved topical levofloxacin on the human ocular surface.
    Bai T; Huang J; Wang W
    Cutan Ocul Toxicol; 2010 Dec; 29(4):247-53. PubMed ID: 20550489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.